Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
$48.36
$3.70(12.70%)
At close: 4:00 PM EST
$48.36
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$23.23 - $49.16
Previous CloseN/A
Volume233.62K
Average Volume (3M)584.86K
Market Cap
$1.54B
Enterprise Value$2.01B
Total Cash (Recent Filing)$305.71M
Total Debt (Recent Filing)$936.27M
Price to Earnings (P/E)30.1
Beta0.34
Next Earnings
Feb 19, 2026EPS Estimate
2.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding31,610,975
10 Day Avg. Volume499,815
30 Day Avg. Volume584,859
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)4.04
Price to Sales (P/S)1.46
P/FCF Ratio4.55
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit4.64
Enterprise Value/Ebitda5.12
Forecast
1Y Price Target
$50.00Price Target Upside3.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)7.48
Revenue Forecast (FY)$751.63M
Bulls Say, Bears Say
Bulls Say
Cash Flow And LeverageOperating cash flow reached $78.4M for the quarter, and net leverage declined to ~1.2x adjusted EBITDA, with expectations to reduce net leverage below 1.0x by year-end 2025.
Financial PerformanceCOLL reported third-quarter 2025 results that exceeded both revenue and EPS expectations and drove an increase in net revenue, Jornay revenue, and adjusted EBITDA guidance for 2025.
Growth InitiativesCOLL's recent commercial initiatives, including an expanded 180-rep ADHD sales force, enhanced digital and social media marketing, and new patient-support resources are expected to drive continued growth in 2026 and beyond.
Bears Say
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $23.23 and its highest was $49.16 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $1.54B.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Feb 19, 2026 which is in 68 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Nov 06, 2025. The company reported $2.25 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.39.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 2.15.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 31,610,975 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $2.25 in its last earnings report, beating expectations of $1.86. Following the earnings report the stock price went up 13.417%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
Collegium Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.00 (3.39% Upside)
$50.00 (3.39% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 328.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 20.2%
Last 30 Days ▲ 57.3%
Last 30 Days ▲ 57.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.97%
12-Months-Change
Fundamentals
Return on Equity
22.96%
Trailing 12-Months
Asset Growth
-1.70%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative products for the treatment of pain and addiction. The company focuses on formulating and marketing prescription medications that address the opioid crisis and chronic pain management. Collegium's core products include Xtampza ER, an abuse-deterrent extended-release formulation of oxycodone, and other product candidates aimed at improving patient outcomes while minimizing the risk of misuse.
COLL Company Deck
COLL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Collegium Pharmaceuticals reported a strong quarter with record revenues and growth across key product lines, particularly Jornay PM and the pain portfolio. The company has shown effective strategic capital deployment and increased financial guidance for 2025, indicating confidence in continued growth. However, there are some concerns regarding gross to net variability and the delayed impact of sales force expansion.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$50.00
▲(3.39% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
Currently, No data available
---